Investor Relations Resource Center
From the Frontlines of Healthcare IR
We're sharing insights from our experienced team of data-driven industry leaders in healthcare investor relations and external communications. Check back for new monthly newsletters, video interviews, and other free offerings to help you reach your financing goals.
Our people work hard, and they do it together.
What We’re Doing
How Hyperlocal Dynamics Are Redefining Market Access
Eddie Vogel, Ph.D. | Vice President, Consulting Greg Gregory, Ph.D. | Executive Vice President, Partner
Why IDNs Are Becoming the Most Important Access Stakeholder
Angelica Norrell, PharmD, BCOP, CSP | Senior Director, Access Experience Team
Sign up for our monthly newsletter
2026 Access to the Best and Brightest: Video Interview Series
Surge
Precision AQ's Best and Brightest 2026 caught up with Michael Goldberg, Chief Executive Officer of Surge Therapeutics, at JPM 2026 to discuss how Surge is addressing post-surgical cancer recurrence and metastasis through intraoperative immunotherapy.
Reunion
Precision AQ’s Best and Brightest 2026 sat down with Greg Mayes, President & CEO of Reunion Neuroscience, at JPM 2026 to discuss advancing next‑generation, psychedelic‑inspired therapeutic solutions for underserved mental health disorders.
Pheast
Precision AQ’s Best and Brightest 2026 caught up with Roy Maute, Cofounder and CEO of Pheast Therapeutics, to discuss how they are developing new innate immune checkpoint inhibitors to unlock the power of macrophages on aggressive cancers.
Luminary
Precision AQ’s Best and Brightest 2026 met up with Jeff Liter, the President and CEO of Luminary Therapeutics, to discuss their next-generation multiantigen CAR T-cell therapies in development for oncology and autoimmune disease.Leapfrog
Precision AQ sat down with Greg Vontz, the CEO of Leapfrog Bio at JPM 2026 to discuss their unique OncoSLX drug discovery platform and development plans for LFB190 targeting a range of cancers with EP300 mutations, including NSCLC, bladder cancer, and more.Ironwood
Precision AQ’s Best and Brightest 2026 sat down with Ironwood’s Chief Commercial Officer, Tammi Gaskins, and Chief Financial Officer, Greg Martini, at JPM 2026 to discuss advancing treatments for gastrointestinal and rare disease disorders.Faeth
Continuing Precision AQ’s Best and Brightest series, we spoke with CEO & Founder of Faeth Therapeutics, Anand Parikh, about Faeth’s approach to cancer and multi-node therapies under development.Esperion
Sheldon Koenig, President and CEO of Esperion Therapeutics, joined Precision AQ’s Best and Brightest to discuss anticipated changes to cardiology therapy landscape in 2026, and the company’s Vision 2040 growth strategy.
Dewpoint
Precision AQ’s Best and Brightest 2026 sat down with Dewpoint Therapeutics’ CEO, Ameet Nathwani, and CSO, Isaac Klein, at JPM 2026 to discuss how they are applying condensate-targeted drug discovery to address historically undruggable targets in the oncology and neurodegeneration space.
Athira
Precision AQ was joined by Mark Mitton, President and CEO of LeonaBio, formerly Athira Pharma, for a Best & Brightest discussion around the company’s new identity and their clinical programs in development for metastatic breast cancer and ALS.Archived Video Series
Precision Bioscience
To kick off the year at the Precision AQ Corporate Access event in San Francisco, Precision AQ EVP & Managing Director, Hannah Deresiewicz, sat down with Precision BioSciences, Inc. CFO Alex Kelly. They discussed the company's proprietary ARCUS® in vivo gene editing platform and its Phase 1 ELIMINATE-B trial for chronic hepatitis B, which recently announced initial safety and substantial antiviral activity in the first cohort of patients after first administration of PBGENE-HBV.
ProMIS Neurosciences
ProMIS Neurosciences CEO, Neil Warma, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event in San Francisco. They talked about the Alzheimer’s disease landscape and the progress of ProMIS’ lead candidate, PMN310.
Reunion
Reunion Neuroscience’s CEO Greg Mayes sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz at the J.P. Morgan Healthcare Conference earlier this year. They discussed the company’s efforts to revolutionize the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions.
Spur Therapeutics
This January in San Francisco, Precision AQ EVP & Managing Director Hannah Deresiewicz sat down with Spur Therapeutics CEO Michael Parini at the J.P. Morgan Healthcare Conference. They discussed how Spur is pushing the boundaries of gene therapy through a redefined approach of developing gene therapies for treatment of serious chronic diseases.
Resolution
Resolution Therapeutics CEO, Amir Hefni, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event San Francisco. They highlighted the company’s latest progress in their lead asset RTX001, a Regenerative Macrophage Therapy for end-stage liver disease.
Esperion
Esperion CEO, Sheldon Koenig, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event last month in San Francisco. They talked about Esperion’s progress advancing innovative medicines that help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.